To promote the development of near-infrared (NIR) light sources in optoelectronic and biomedical applications, the discovery of NIR-emitting phosphor materials and their design principles are essential. Herein, we report a novel Eu 2+ -activated broadband NIR-emitting phosphor, BaSrGa 4 O 8 :Eu 2+ , which features multisite occupation due to Ba/Sr and oxygen site occupancy disorder. With an increase in the Ba/Sr atomic ratio from 1:1 to 1.7:0.3, the Eu 2+ emission band maximum red-shifts from 670 to 775 nm, along with an enlargement of the full width at half-maximum (FWHM) from 140 to 230 nm. The underlying mechanism for the structure−property relationship is elucidated using density functional theory calculations. The application of the NIR phosphor-converted light-emitting diodes (pc-LEDs) is demonstrated, showing their potential in night-vision technology. Our results can initiate further exploitation of the host structural disorder toward Eu 2+ broadband NIR luminescence for applications in pc-LEDs.

No abstract

No abstract

No abstract

Gastric cancer (GC) is a prevalent malignant tumor of the digestive system worldwide, ranking among the top five in terms of incidence and mortality. However, the clinical efficacy of conventional treatments for gastric cancer remains limited, with a median overall survival of approximately eight months for advanced cases. In recent years, researchers have increasingly focused on antibody-drug conjugates (ADCs) as a promising approach. ADCs are potent chemical drugs that selectively target cancer cells by binding to specific cell surface receptors with antibodies. Notably, ADCs have demonstrated promising results in clinical studies and have made significant strides in the treatment of gastric cancer. Currently, several ADCs are under investigation in clinical trials for gastric cancer patients, targeting various receptors such as EGFR, HER-2, HER-3, CLDN18.2, Mucin 1, among others. This review offers a comprehensive exploration of ADC drug characteristics and provides an overview of the research progress in ADC-based therapies for gastric cancer.